A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell, Elizabeth K. 1,2; Laubach, Jacob P. 2,3; Yee, Andrew J. 1,2,4; Chen, Tianqi 3; Huff, Carol Ann 5; Basile, Frank G. 6; Wade, Philip M. 6; Paba-Prada, Claudia E. 2,3; Ghobrial, Irene M. 2,3; Schlossman, Robert L. 2,3; Burke, Jill N. 1; Harrington, Cynthia C. 1; Lively, Kathleen J. 1; Lyons, Hannah F. 4; Munshi, Nikhil C. 2,3; Anderson, Kenneth C. 2,3; Trippa, Lorenzo 3; Richardson, Paul G. 2,3; Raje, Noopur S. *,1,2
[Miscellaneous Article]
British Journal of Haematology.
182(2):222-230, July 2018.
(Format: HTML, PDF)